SUPERNUS PHARMACEUTICALS, INC. — Form 8-K
Filed August 3, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Indivior Pharmaceuticals and Supernus Pharmaceuticals signed a definitive merger agreement dated August 1, 2026, whereby Indivior will acquire Supernus in an all-stock transaction. Supernus shareholders will receive 1.5401 Indivior shares per Supernus share held (the Exchange Ratio). The combined company will be renamed Supernus, Inc., trade under Supernus's existing ticker, and be governed with equal board representation (50/50 split between Indivior and Supernus designees), with an Indivior designee as Chair and Supernus's existing CEO/CFO/senior management continuing in those roles.
Why this rating
Material M&A at ~2.4x Supernus market cap (58.2M shares × 1.5401 Indivior shares at ~$14.4B Indivior value = ~$1.3B Supernus consideration vs $1.7B market cap). Merger of equals structure, equal board seats, and existing Supernus management retention are favorable. Positive for scale and portfolio, though regulatory and financing risks remain pre-closing.
See more from August 3, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.